400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
ChiCTR-IPR-15007056
尚未开始
甲羟孕酮
/
甲羟孕酮
2015-09-15
/
/
uterine fibroid
甲羥孕酮 (DMPA) 及促性腺激素釋放激素 (GnRHa) 於患子宮肌瘤的絕經前婦女之治療效果之研究 (隨機雙盲對照試驗)
甲羥孕酮 (DMPA) 及促性腺激素釋放激素 (GnRHa) 於患子宮肌瘤的絕經前婦女之治療效果之研究 (隨機雙盲對照試驗)
甲羥孕酮 (DMPA) 及促性腺激素釋放激素 (GnRHa) 於患子宮肌瘤的絕經前婦女之治療效果
随机平行对照
Ⅳ期
Random
/
Department of Obstetrics & Gynaecology, the Chinese University of Hong Kong
/
203
/
1990-01-01
1990-01-01
/
1. 18-50 years old; 2. Women with at least one fibroid >=3cm; 3. Pictorial blood loss assessment chart (PBAC) score more than 100 (~80ml) for 2 months; 4. Uterine size more than or equal to 12 weeks; 5. Uterine size less than 12 weeks; 6. Refuse or fail LNG-IUS or endometrial ablation.;
请登录查看1. Menopaul women; 2. Women planning for pregnancy; 3. Women with gynaecological premalignant or malignant uterine pathologies; 4. Women with type 1 submucol uterine fibroid; 5. Contraindication to the use of DMPA or GnRHa; 6. Women with concomitant endometrioma >5cm and/or adenomyosis/adenomyoma; 7. Concomitant use of Chinese herbal medicine/ hormonal replacement therapy/tamoxifen; 8. Coagulation problem or using medication which affect clotting function; 9. Use of DMPA/GnRHa in past 6 months; 10. Uncontrolled thyroid dysfunction.;
请登录查看The Chinese University of Hong Kong
/
求实药社2026-03-05
生物制品圈2026-03-05
医药观澜2026-03-05
医药观澜2026-03-05
河北省干细胞中心2026-03-05
生物制药小编2026-03-05
一度医药2026-03-05
炎明生物Pyrotech2026-03-05
药明康德2026-03-05
疑夕随笔2026-03-04